Regeneron Pharmaceuticals Inc. has announced its successful bid to acquire the majority of assets from 23andMe Holding Co. for $256 million. This acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and Biobank, aiming to maintain consumer genomics services without interruption. The transaction, pending bankruptcy court and regulatory approvals, is expected to finalize in the third quarter of 2025. Regeneron plans to operate 23andMe as a subsidiary, excluding its Lemonaid Health business, and emphasizes its commitment to customer data privacy and ethical use.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.